Nocera, Inc. Form 8-K Summary
Business Context and Reporting Period
Nocera, Inc., a Nevada corporation headquartered in New Taipei City, Taiwan, filed a Form 8-K dated August 10, 2022, reporting entry into agreements related to an underwritten public offering. The offering closed on August 15, 2022; the filing was signed on August 16, 2022. Nocera’s common stock trades on Nasdaq under the symbol NCRA. The company identifies as an emerging growth company.
Offering and Key Financial Terms
- The company offered 1,880,000 units at $3.50 per unit.
- Each unit consisted of one common share and one warrant exercisable for two common shares.
- The warrants are exercisable for five years from issuance at $3.85 per share, subject to customary anti-dilution adjustments.
- Gross proceeds were $6.58 million; net proceeds after underwriting commissions, discounts, and offering expenses were approximately $5.3 million.
- The underwriters received units at a purchase price of $3.22 per unit.
- The underwriters received a 45-day over-allotment option for up to 282,000 additional units.
- Spartan Capital Securities received a representative warrant for up to 94,000 shares, exercisable at $3.85 per share from February 11, 2023 through August 11, 2027.
- The warrants are not intended to be listed on a national securities exchange or quoted on an interdealer quotation system.
Material Changes and Other Events
- The offering increased the company’s cash resources by approximately $5.3 million net, while issuing 1,880,000 common shares and warrants potentially exercisable for 3,760,000 additional shares, excluding any over-allotment exercise.
- Common stock began trading on Nasdaq on August 10, 2022, on a 2-for-3 post-reverse-stock-split basis.
- The company entered into a warrant agency agreement with Mountain Share Transfer LLC on August 11, 2022.
Guidance, Outlook, Risks, and Unusual Items
The filing does not provide operating guidance, revenue or earnings forecasts, cash-flow projections, or management commentary regarding the use of proceeds. Key considerations include potential dilution from the public warrants, representative warrant, and any exercised over-allotment option. The underwriting agreement contains customary representations, warranties, covenants, and indemnification provisions. The filing text does not specify the company’s post-offering cash balance, debt, liquidity runway, or planned allocation of proceeds.
Investor Verification Items
- Verify whether the underwriters exercised any portion of the 282,000-unit over-allotment option.
- Confirm the final number of shares and warrants issued at closing and the resulting fully diluted share count.
- Review the full warrant terms for adjustment provisions and other exercise conditions.
- Confirm the company’s intended use of the approximately $5.3 million in net proceeds.
- Review subsequent filings for the offering’s effect on liquidity, operating performance, and potential dilution.